Pharmafile Logo

From activity to impact: 5 takeaways from MAPS Americas 2026

June 2, 2026 |  

Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now being actively implemented, with teams moving beyond theory and into execution.

- PMLiVE

Here are five key takeaways shaping the future of Medical Affairs.

1. Medical Affairs is stepping into a strategic leadership role

Medical Affairs is no longer operating at the margins of strategy. It is increasingly being brought earlier into the development process, co-leading product launchesin some situations functionally leading product launch, and influencing enterprise decision-making.  

As Gemma Pfister (Senior Consulting Executive, Inizio Ignite) and Eric Wood (Head of Commercial, Transformation, Inizio Ignite) observed, teams are now “required to translate complex science into enterprise value,” reflecting a fundamental shift in expectations.  

There is also a growing emphasis on engaging at a more senior level. Varun Renjen (Partner, Inizio Ignite) highlighted the importance of Medical Affairs leaders being able to “speak the pipeline, the top line and the bottom line,” reinforcing the need for commercial fluency alongside scientific expertise.  

This evolution marks a turning point. Medical Affairs is not just supporting strategy, it is helping define it.

2. The shift from activity to impact is accelerating

A consistent theme throughout MAPS was the need to move beyond activity-based metrics and demonstrate real, measurable impact. 

Jo Ann Saitta (Head of Data & AI, Inizio Ignite), pointed to the growing focus on “where they are moving the needle on patient impact,” with teams increasingly leveraging real-world data to demonstrate changing behaviors and value.  

Importantly, this is not about proving value for the first time. As Eric Wood reflected, “medical has already reached the milestone of proving effectiveness.” The challenge now is to communicate that value more clearly and consistently across the organization.  

Dean McAlister (Executive Vice President, Biotech Enterprise Solutions, Inizio Biotech) captured this shift powerfully, highlighting the importance of bringing data to life through storytelling: “we move it from hands and feet to the hearts and minds of the people involved.”  

The implication is clear. Demonstrating impact is no longer optional. It is a core capability for Medical Affairs teams.

Read the full blog here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

20 questions: Round 4

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What’s been the funniest thing to happen to you whilst you’ve...

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of...

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog...

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global...

TRIO OF HIRES SIGNAL PEGASUS’ NORTHERN GRIT

Growth trend continues at ‘health first, sector second’ agencyPegasus, an Ashfield company, part of UDG Healthcare plc, has announced further growth of its Pharma and Life Sciences division with the...

PEGASUS SCOOPS EXCELLENCE IN INTEGRATED PRODUCT/BRAND COMMUNICATIONS AT COMMUNIQUÉ 2017

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the Excellence In Integrated Product/Brand Communications award at the 2017 Communiqué awards for its work with...

EphMRA 2017 round up

We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.

Taking a hybrid qualitative-quantitative approach to research

Directors Phil Rosenberg and Chris Gaj discuss ways to achieve qualitative insights with quantitative precision and the benefits of a hybrid approach.Watch the video: https://www.researchpartnership.com/news/2017/06/video-taking-a-hybrid-qualitative-quantitative-appr...